The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2024 | Employing CAR-T therapies in earlier lines of large B-cell lymphoma treatment
Paolo Cortesi, MD, University of Milan-Bicocca, Milan, Italy, summarizes the emerging CAR-T treatment landscape for earlier lines of treatment in patients with large B-cell lymphoma (LBCL). Considering the results of the Phase III ZUMA-7 trial (NCT03391466) of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory LBCL, Dr Cortesi highlights the value of earlier axi-cel administration and the importance of ensuring that specialized centers are equipped to provide CAR-T to a larger patient population. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Novartis: Honoraria; Roche: Honoraria; Almirall: Honoraria; Otsuka: Honoraria.
